Bruce Cozadd sells 6,000 Jazz (NASDAQ: JAZZ) shares under 10b5-1 plan

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of Jazz Pharmaceuticals on May 1, 2026, at $203.33 per share. After this transaction, he directly holds 378,682 Ordinary Shares.

According to the filing, this sale was executed automatically under a pre-arranged trading plan adopted on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, meaning the timing did not involve a discretionary decision by Cozadd.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares ($1,219,980)

Net Sell 1 txn

Insider COZADD BRUCE C

Role null

Sold 6,000 shs ($1.22M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,000	$203.33	$1.22M

Holdings After Transaction: Ordinary Shares — 378,682 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 6,000 shares Sale price: $203.33 per share Shares held after sale: 378,682 shares

3 metrics

Shares sold 6,000 shares Open-market sale on May 1, 2026

Sale price $203.33 per share Price for 6,000 Ordinary Shares sold

Shares held after sale 378,682 shares Direct ownership following the transaction

Key Terms

open-market sale, Rule 10b5-1, Securities Exchange Act of 1934

3 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 regulatory

"plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Securities Exchange Act of 1934 regulatory

"in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/01/2026		S(1)		6,000	D	$203.33	378,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Bruce C. Cozadd?

Bruce C. Cozadd reported an open-market sale of 6,000 Jazz Pharmaceuticals Ordinary Shares. The sale occurred on May 1, 2026 at $203.33 per share and was disclosed in a Form 4 insider transaction filing.

At what price did Bruce C. Cozadd sell Jazz Pharmaceuticals (JAZZ) shares?

He sold 6,000 Ordinary Shares at $203.33 per share. This price reflects the sale value reported in the Form 4 filing, documenting an open-market transaction in Jazz Pharmaceuticals stock on May 1, 2026.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce C. Cozadd hold after this sale?

Following the reported sale, Bruce C. Cozadd directly holds 378,682 Ordinary Shares of Jazz Pharmaceuticals. This post-transaction balance is stated in the Form 4 and shows his remaining direct ownership after the 6,000-share sale.

Was Bruce C. Cozadd’s Jazz Pharmaceuticals (JAZZ) share sale discretionary?

No. The filing states the transaction occurred automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025. Such plans pre-schedule trades, so the timing of this sale was not a discretionary decision by Cozadd.

What is the significance of the Rule 10b5-1 plan in Bruce C. Cozadd’s JAZZ share sale?

The Form 4 notes the sale was made under a Rule 10b5-1 trading plan. This means trades were pre-arranged when Cozadd was not trading on material nonpublic information, and the sale occurred automatically according to that preset plan.